To the Editor,
Autoimmune hemolytic anemia (AIHA) can emerge at any stage of chronic lymphocytic leukemia (CLL); furthermore, patients can present with AIHA before diagnosis [1]. Although direct antiglobulin test (DAT) positivity is one of the hallmarks of AIHA, it was also demonstrated to be associated with advanced disease [2] and poor prognosis [3] independent of hemolytic anemia in CLL patients [3]. Here we present two CLL patients with AIHA whose DAT results became negative shortly after receiving bendamustine-rituximab (BR) chemotherapy.
Case 1
A 69-year-old male patient who was being followed without treatment for CLL in Rai stage 2 for 6 months presented with abdominal pain and jaundice. Laboratory tests were as follows: leukocytes: 55,140/µL, lymphocytes: 51,240/µL, hemoglobin: 5.3 g/dL, platelets: 46,000/µL, indirect bilirubin: 2.89 mg/dL, haptoglobin: 2 mg/dL, lactate dehydrogenase (LDH): 1585 U/L, and DAT positive for Immunoglobulin G (IgG) (no titer provided). Imaging studies showed compressing conglomerate lymph node masses in the abdomen. The patient was started on steroid and BR treatments. The hemoglobin value rose to normal levels and DAT became negative after 3 cycles of BR. The patient received 6 cycles of BR chemotherapy and steroids were interrupted at the 5th month of treatment. The patient has been followed in remission for 1 year.
Case 2
A 75-year-old female patient who was being followed without treatment with the diagnosis of CLL in Rai 0 stage for 8 years was admitted due to weakness and fatigue. Laboratory tests were as follows: leukocytes: 78,840/µL, lymphocytes: 67,020/µL, hemoglobin: 6.3 g/dL, platelets: 255,000/µL, indirect bilirubin: 2.58 mg/dL, LDH: 504 U/L, haptoglobin: 1 mg/dL, corrected reticulocyte count: 5.2%, and DAT positive for IgG (4+). The patient was started on steroid treatment and subsequently BR therapy was added due to increased lymphocyte doubling time. After the first cycle, the DAT titer dropped to 3+. Hemoglobin value rose to normal levels and DAT became negative after 3 cycles of BR. Steroids were ceased at the 7th month of treatment; The patient completed 6 cycles of BR and has been followed in remission for 1 year.
While the standard approach in CLL patients with AIHA is steroids, systemic chemotherapy is recommended in refractory cases and in patients requiring treatment for CLL [1]. Although first-line therapy in CLL patients is the fludarabine-cyclophosphamide-rituximab regimen, the wide use of BR chemotherapy, especially in advanced-age patients, has brought up the application of this combination in patients with AIHA [4,5]. In a recent study including 26 CLL patients who had AIHA and received BR, the response rate was 81% for AIHA and 77% for CLL [4]. Similarly, our patients also responded well in terms of CLL and AIHA. The most striking point was that DAT became negative in a short period of time (after 3 cycles of BR).
In conclusion, in addition to being a plausible option in advanced-age CLL patients, BR seems to be an important treatment of choice in terms of eliminating the poor prognostic factor of DAT positivity and assuring safe cessation of steroid treatment due to rapid achievement of DAT negativity.
Footnotes
Informed Consent: Informed consent was obtained from both patients.
Conflict of Interest: The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.
References
- 1.Zent CS, Kay NE. Autoimmune complications in chronic lymphocytic leukaemia (CLL) Best Pract Res Clin Haematol. 2010;23:47–59. doi: 10.1016/j.beha.2010.01.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Abbas SA, Zeeshan R, Sultan S, Irfan SM. Direct Coombs test positivity in B-chronic lymphoid leukemia: a marker of advanced clinical disease. Asian Pac J Cancer Prev. 2015;16:6007–6010. doi: 10.7314/apjcp.2015.16.14.6007. [DOI] [PubMed] [Google Scholar]
- 3.Quinquenel A, Al Nawakil C, Baran-Marszak F, Eclache V, Letestu R, Khalloufi M, Boubaya M, Le Roy C, Varin-Blank N, Delmer A, Levy V, Ajchenbaum-Cymbalista F. Old DAT and new data: positive direct antiglobulin test identifies a subgroup with poor outcome among chronic lymphocytic leukemia stage A patients. Am J Hematol. 2015;90:5–8. doi: 10.1002/ajh.23861. [DOI] [PubMed] [Google Scholar]
- 4.Quinquenel A, Willekens C, Dupuis J, Royer B, Ysebaert L, De Guibert S, Michallet AS, Feugier P, Guieze R, Levy V, Delmer A. Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: a multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS) Am J Hematol. 2015;90:204–207. doi: 10.1002/ajh.23909. [DOI] [PubMed] [Google Scholar]
- 5.Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017;92:946–965. doi: 10.1002/ajh.24826. [DOI] [PubMed] [Google Scholar]